Trial Profile
Phase II, proof of concept, randomized, placebo-controlled, double-blind trial of Eicosapentaenoic-acid-free-fatty-acid (TP-252) in ulcerative-colitis patients already on therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 May 2018
Price :
$35
*
At a glance
- Drugs Eicosapentaenoic acid free fatty acid (Primary)
- Indications Ulcerative colitis
- Focus Proof of concept; Therapeutic Use
- 29 May 2018 New trial record